Novartis Loses Glivec Patent Fight In India

Law360, New York (July 6, 2009, 12:00 AM EDT) -- A patent tribunal in India has rejected Novartis AG’s bid to secure a patent for its cancer drug Glivec, marking the latest chapter in the Swiss drugmaker's long-running battle with Indian patent law.

A Novartis representative confirmed Tuesday that India's Intellectual Property Appellate Board had denied a Novartis appeal of the Indian Patent Office's 2006 rejection of a patent for Glivec in beta crystal form.

In its ruling, the IPAB upheld objections to the patent under a legal provision unique to Indian patent law, the company...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.